A Trial for Patients With Advanced/Recurrent Cervical Cancer
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV
over 10 minutes in patients with recurrent cervical cancer.